1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza Group Ltd. Appoints Marion Helmes as Independent Member of the Board of Directors, with Effect from May 5, 2022

01/26/2022 | 09:30am EDT

Marion Helmes has been appointed as an independent member of the Board of Directors of LONZA Group Ltd, with effect from 5 May 2022.


ę S&P Capital IQ 2022
All news about LONZA GROUP AG
09:26aLonza Opens New Facility for Kodiak Sciences' Retinal Diseases Drug
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09LONZA GROUP AG : Ex-dividend day for Distribution from share premium account
FA
05/09LONZA GROUP AG : Ex-dividend day for final dividend
FA
05/06EuroAPI gains on market debut after spin-off from Sanofi
RE
05/05LONZA GROUP AG : Proxy Statments
CO
04/29LONZA : to Divest its Quakertown Site Specialized in Particle Size Reduction; Business to ..
PU
04/29Investor group led by Derek Hennecke, TJ Higley, Mark Bamforth, Bill Mitchell and other..
CI
04/26Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using ..
AQ
04/25Lonza Joins Integral Molecular to Offer De-risking of Biotherapeutics
MT
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 128 M 6 174 M 6 174 M
Net income 2022 1 055 M 1 062 M 1 062 M
Net cash 2022 339 M 342 M 342 M
P/E ratio 2022 38,9x
Yield 2022 0,60%
Capitalization 41 012 M 41 313 M 41 313 M
EV / Sales 2022 6,64x
EV / Sales 2023 5,91x
Nbr of Employees 16 218
Free-Float 98,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 552,80 CHF
Average target price 800,68 CHF
Spread / Average Target 44,8%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Werner J. Bauer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-27.42%41 313
MODERNA, INC.-43.98%56 593
IQVIA HOLDINGS INC.-26.74%39 122
SEAGEN INC.-5.21%26 976
ICON PUBLIC LIMITED COMPANY-32.47%17 002
ALNYLAM PHARMACEUTICALS, INC.-26.37%15 622